About Manisha Samy, ARK Analyst
Manisha joined ARK as a thematic analyst on the Genomic Revolution team in February 2016. Her focus is on Instrumentation, Targeted Therapeutics, Agricultural Biology, Diagnostics and Stem Cells.
Prior to ARK, Manisha worked as a management consultant for Kepler Cannon. Before that, she gained experience as a business solution analyst at Attensity America. Manisha graduated from Stanford with a Bachelor of Science in Science, Technology, and Society: Life Sciences and Biotechnology.
Research by Manisha Samy, ARK Analyst
November 02, 2017 | by Manisha Samy, ARK Analyst | Health
The debate over drug pricing has intensified significantly after the recent approval of two CAR-T therapies, Kymriah and Yescarta. CAR-T is a type of gene therapy that harnesses a patient’s immune system to attack and kill cancer cells, providing a potential cure for metastatic cancer. Kymriah was the first CAR-T approved, for pediatric acute lymphoblastic […]September 15, 2017 | by Manisha Samy, ARK Analyst | Health
Genome-Editing During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in biotechnology and synthetic biology: now research is focused not on “treatment” of diseases but on its modification and cure. The ability to directly edit living cells has brought gene therapy and precision medicine into […]June 22, 2017 | by Manisha Samy, ARK Analyst | Health
Discovered nearly thirty years ago in 1988, stem cell technology has failed to transform the field of regenerative medicine…until now. After delivering only one treatment during three decades of development, stem cell technology could finally become the all-purpose tool for repairing the body, thanks to rapid and precise genome editing techniques such as CRISPR and […]April 18, 2017 | by Manisha Samy, ARK Analyst | Health
An Alzheimer’s treatment that converts the neurodegenerative disease from a cruel killer into a tolerable chronic condition could become the best selling drug in history.1 According to ARK’s estimates, the annual revenue associated with an effective Alzheimer’s treatment could approximate to $120 billion USD.2 While many companies have attempted to develop an effective treatment, not one has […]January 12, 2017 | by Manisha Samy, ARK Analyst | Health
The Promise DNA (Deoxyribonucleic acid) is the “source code” of life, and now we can edit and correct that code efficiently and cost-effectively should there be a disease-causing error. In other words, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing could save millions of lives and cure thousands of genetic disorders, if it is to […]August 25, 2016 | by Manisha Samy, ARK Analyst | Health
Prime Time for Companion Diagnostics We think the drug approval process remains convoluted, costly, and time-consuming, but it is about to change. The increased adoption of Companion Diagnostics (CDx)—tests that identify the most suitable patients for a particular treatment—holds much promise. ARK expects that CDx will improve patient outcomes demonstrably, reduce research and development spending […]March 18, 2016 | by Manisha Samy, ARK Analyst | Health
Amid a global epidemic, the Food and Drug Administration (FDA) has issued new guidelines for blood banks to prevent the contamination and transmission of the Zika virus. While whole blood donations are banned in Zika-endemic parts of the world, Cerus INTERCEPT would enable the safe collection and transfusion of plasma and platelets. Two years after […]